Interaction now - cerebral small vessel disease and Alzheimer’s disease
30th Paulo Foundation International Medical Symposium
28-29 October 2021, Virtual Only, from Helsinki, Finland
28-29 October 2021, Virtual Only, from Helsinki, Finland
Official symposium time zone Central European Summer Time, CEST
Thursday 28 October
9.00-9.15 CEST | Opening. Anne Koivisto, Susanna Melkas, Hanna Jokinen. Helsinki, Finland | |
9.15-10.30 CEST | Neuropathology. ApoE and microglia. - Moderator Liisa Myllykangas, Helsinki, Finland. | |
9.15 CEST | Raj Kalaria, Newcastle, UK Update on the pathophysiology of sporadic and familial cerebral small vessel diseases with implications for Alzheimer’s disease |
|
9.45 CEST | Tarja Malm, Kuopio, Finland Regulators of microglial functions: focus on ApoE |
|
10.15 CEST | 12 min discussion, 3 min break | |
10.30-11.45 CEST | Neuroinflammation. Glymphatic system. - Moderator Perttu Lindsberg, Helsinki, Finland. | |
10.30 CEST | Pentti Tienari, Helsinki, Finland Major histocompatibility complex (MHC) and neuroinflammation |
|
11.00 CEST | Tuomas Lilius, Helsinki, Finland Pharmacology of the glymphatic system - implications for neurodegenerative diseases |
|
11.30 CEST | 15 min discussion | |
11.45-12.30 CEST | BREAK | |
12.30-13.45 CEST | From clinics to research and back, part I. - Moderator Anne Koivisto, Helsinki, Finland. | |
12.30 CEST | Leonardo Pantoni, Milano, Italy How can we detect SVD and degenerative components in our clinical practice and in research? |
|
13.00 CEST |
Miia Kivipelto, Stockholm, Sweden |
|
13.30 CEST | 12 min discussion, 3 min break | |
13.45-15.25 CEST | From imaging to cognitive and functional status. - Moderator Susanna Melkas, Helsinki, Finland. | |
13.45 CEST | Mark Bondi, San Diego, US Associations of MRI locus coeruleus contrast ratio and white matter lesion pathology in nondemented older adults |
|
14.15 CEST | 5 min discussion | |
14.20 CEST | Hanna Jokinen, Helsinki, Finland Global burden of SVD brain changes |
|
14.50 CEST |
Adam Brickman, New York, US |
|
15.20 CEST |
15 min discussion | |
15.35-15.45 CEST |
Closing of the day |
Friday 29 October
9.00 -10.00 CEST |
Oral presentations. - Moderators Anne Koivisto and Susanna Melkas, Helsinki, Finland. 9.00-9.15 CEST Ruiting Zhang, Zhejiang University, China. Venous disruption affects white matter integrity through increased interstitial fluid in cerebral small vessel disease. 9.15-9.30 CEST Viivi Jetsonen, University of Eastern Finland, Finland. Total cost of care increases significantly from early to mild Alzheimer’s disease: 5-year ALSOVA follow-up. 9.30-9.45 CEST Phoebe Evans, University College London, UK. Cardiac-rhythm linked perivascular fluid movement reduced in pharmacological model of hypertension: a non-invasive MRI study. 9.45-10.00 CEST Anne Arola, University of Helsinki, Finland. Depressive symptoms exacerbate cognitive and functional impairment related to covert small vessel disease. |
|
10.00-11.15 CEST | Biomarkers, early diagnostics. - Moderator Anne Remes, Oulu, Finland. | |
10.00 CEST | Henrik Zetterberg, Gothenburg, Sweden Development of blood biomarkers for neurodegenerative dementias - goodbye lumbar puncture? |
|
10.30 CEST |
Sanna-Kaisa Herukka, Kuopio, Finland |
|
11.00 CEST | 12 min discussion, 3 min break | |
11.15-12.30 CEST | From clinics to research and back, part II. - Moderator Marja Hietanen, Helsinki, Finland. | |
11.15 CEST | Anders Wallin, Gothenburg, Sweden The relevance of the neurovascular unit in patients with subcortical small-vessel disease |
|
11.45 CEST | Olivier Godefroy, Amiens, France Poststroke cognitive disorders and their imaging determinants |
|
12.15 CEST | 15 min discussion | |
12.30-13.15 CEST | BREAK | |
13.15-14.30 CEST | Treatment perspectives. - Moderator Lauri Soinne, Helsinki, Finland. | |
13.15 CEST | Vincent Mok, Hong Kong, China Preventive treatments of sporadic cerebral small vessel disease |
|
13.45 CEST | Satu Palva, Helsinki, Finland Computational model to stimulate brain function for the diagnosis and individualized treatment of degenerative brain diseases (VirtualBrainCloud) |
|
14.15 CEST | 12 min discussion, 3 min break | |
14.30-15.10 CEST | Future trials, interaction. - Moderator Susanna Melkas, Helsinki, Finland. | |
14.30 CEST | Terry Quinn, Glasgow, UK What would a cSVD/AD trial look like? |
|
15.00 CEST | 10 min discussion | |
15.10-15.20 CEST | Closing |
The program may be subject to change.